Evidence map›Paper›PMID 27758828›Full record

SynthesisJournal of the National Cancer Institute2016

Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.

Ruth C Travis, Angela Balkwill, Georgina K Fensom, Paul N Appleby, Gillian K Reeves, Xiao-Si Wang, Andrew W Roddam, Toral Gathani, Richard Peto, Jane Green and 2 more

Abstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the National Cancer Institute, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Shift work and health outcomes: an umbrella review of systematic reviews and meta-analyses of epidemiological studies.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP) ruth.travis@ceu.ox.ac.uk.
Angela BalkwillCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Georgina K FensomCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Paul N ApplebyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Gillian K ReevesCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Xiao-Si WangCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Andrew W RoddamCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Toral GathaniCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Richard PetoCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Jane GreenCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).
Valerie BeralCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (RCT, AB, GKF, PNA, GKR, XSW, AWR, TG, JG, TJK, VB); Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, UK (AWR); Department of Oncoplastic Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, UK (TG); Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK (RP).

Funding

Cancer Research UK 16491Cancer Research UK 16896Medical Research Council G0700474Medical Research Council G9900923Medical Research Council MC_PC_12028Medical Research Council MC_QA137853Medical Research Council MR/K02700X/1Medical Research Council MR/M012190/1
6 · The paper itself

Abstract

backgroundIt has been proposed that night shift work could increase breast cancer incidence. A 2007 World Health Organization review concluded, mainly from animal evidence, that shift work involving circadian disruption is probably carcinogenic to humans. We therefore aimed to generate prospective epidemiological evidence on night shift work and breast cancer incidence.

methodsOverall, 522 246 Million Women Study, 22 559 EPIC-Oxford, and 251 045 UK Biobank participants answered questions on shift work and were followed for incident cancer. Cox regression yielded multivariable-adjusted breast cancer incidence rate ratios (RRs) and 95% confidence intervals (CIs) for night shift work vs no night shift work, and likelihood ratio tests for interaction were used to assess heterogeneity. Our meta-analyses combined these and relative risks from the seven previously published prospective studies (1.4 million women in total), using inverse-variance weighted averages of the study-specific log RRs.

resultsIn the Million Women Study, EPIC-Oxford, and UK Biobank, respectively, 673, 28, and 67 women who reported night shift work developed breast cancer, and the RRs for any vs no night shift work were 1.00 (95% CI = 0.92 to 1.08), 1.07 (95% CI = 0.71 to 1.62), and 0.78 (95% CI = 0.61 to 1.00). In the Million Women Study, the RR for 20 or more years of night shift work was 1.00 (95% CI = 0.81 to 1.23), with no statistically significant heterogeneity by sleep patterns or breast cancer risk factors. Our meta-analysis of all 10 prospective studies included 4660 breast cancers in women reporting night shift work; compared with other women, the combined relative risks were 0.99 (95% CI = 0.95 to 1.03) for any night shift work, 1.01 (95% CI = 0.93 to 1.10) for 20 or more years of night shift work, and 1.00 (95% CI = 0.87 to 1.14) for 30 or more years.

conclusionsThe totality of the prospective evidence shows that night shift work, including long-term shift work, has little or no effect on breast cancer incidence.

Indexed as

Personnel Staffing and SchedulingWork Schedule ToleranceAdolescentAdultAgedBreast NeoplasmsCircadian RhythmFemaleHumansIncidenceMiddle AgedProspective StudiesSurveys and QuestionnairesUnited KingdomYoung Adult

Identifiers

PMID27758828
PMCPMC5241898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.